Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial

R. Prymula, MR. Bergsaker, S. Esposito, L. Gothefors, S. Man, N. Snegova, M. Stefkovičova, V. Usonis, J. Wysocki, M. Douha, V. Vassilev, O. Nicholson, BL. Innis, P. Willems,

. 2014 ; 383 (9925) : 1313-24.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063743
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 24485548
DOI 10.1016/s0140-6736(12)61461-5
Knihovny.cz E-zdroje

BACKGROUND: Rates of varicella have decreased substantially in countries implementing routine varicella vaccination. Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV). We assessed protection against varicella in naive children administered one dose of varicella vaccine or two doses of MMRV. METHODS: This study was done in ten European countries with endemic varicella. Healthy children aged 12-22 months were randomised (3:3:1 ratio, by computer-generated randomisation list, with block size seven) to receive 42 days apart (1) two doses of MMRV (MMRV group), or (2) MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group), or (3) two doses of MMR (MMR group; control). Participants and their parents or guardians, individuals involved in assessment of any outcome, and sponsor staff involved in review or analysis of data were masked to treatment assignment. The primary efficacy endpoint was occurrence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from 42 days after the second vaccine dose to the end of the first phase of the trial. Cases were graded for severity. Efficacy analyses were per protocol. Safety analyses included all participants who received at least one vaccine dose. This trial is registered with ClinicalTrials.gov, number NCT00226499. FINDINGS: Between Sept 1, 2005, and May 10, 2006, 5803 children (mean age 14·2 months, SD 2·5) were vaccinated. In the efficacy cohort of 5285 children, the mean duration of follow-up in the MMRV group was 36 months (SD 8·8), in the MMR+V group was 36 months (8·5) and in the MMR group was 35 months (8·9). Varicella cases were confirmed for 37 participants in the MMRV group (two moderate to severe), 243 in the MMR+V group, and 201 in the MMR group. Second cases occurred for three participants (all in the MMR+V group). Varicella cases were moderate to severe for two participants in the MMRV group, 37 in the MMR+V group (one being a second case that followed a mild first case); and 117 in the MMR group. Efficacy of two-dose MMRV against all varicella was 94·9% (97·5% CI 92·4-96·6), and against moderate to severe varicella was 99·5% (97·5-99·9). Efficacy of one-dose varicella vaccine against all varicella was 65·4% (57·2-72·1), and against moderate to severe varicella (post hoc) was 90·7% (85·9-93·9). The most common adverse event in all groups was injection-site redness (up to 25% of participants). Within 15 days after dose one, 57·4% (95% CI 53·9-60·9) of participants in the MMRV group reported fever of 38°C or more, by contrast with 44·5% (41·0-48·1) with MMR+V, and 39·8% (33·8-46·1) with MMR. Eight serious adverse events were deemed related to vaccination (three MMRV, four MMR+V, one MMR). All resolved within the study period. INTERPRETATION: These results support the implementation of two-dose varicella vaccination on a short course, to ensure optimum protection from all forms of varicella disease. FUNDING: GlaxoSmithKline Vaccines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063743
003      
CZ-PrNML
005      
20140710093238.0
007      
ta
008      
140704s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(12)61461-5 $2 doi
035    __
$a (PubMed)24485548
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Prymula, Roman $u University Hospital, Hradec Kralove, Czech Republic.
245    10
$a Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial / $c R. Prymula, MR. Bergsaker, S. Esposito, L. Gothefors, S. Man, N. Snegova, M. Stefkovičova, V. Usonis, J. Wysocki, M. Douha, V. Vassilev, O. Nicholson, BL. Innis, P. Willems,
520    9_
$a BACKGROUND: Rates of varicella have decreased substantially in countries implementing routine varicella vaccination. Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV). We assessed protection against varicella in naive children administered one dose of varicella vaccine or two doses of MMRV. METHODS: This study was done in ten European countries with endemic varicella. Healthy children aged 12-22 months were randomised (3:3:1 ratio, by computer-generated randomisation list, with block size seven) to receive 42 days apart (1) two doses of MMRV (MMRV group), or (2) MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group), or (3) two doses of MMR (MMR group; control). Participants and their parents or guardians, individuals involved in assessment of any outcome, and sponsor staff involved in review or analysis of data were masked to treatment assignment. The primary efficacy endpoint was occurrence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from 42 days after the second vaccine dose to the end of the first phase of the trial. Cases were graded for severity. Efficacy analyses were per protocol. Safety analyses included all participants who received at least one vaccine dose. This trial is registered with ClinicalTrials.gov, number NCT00226499. FINDINGS: Between Sept 1, 2005, and May 10, 2006, 5803 children (mean age 14·2 months, SD 2·5) were vaccinated. In the efficacy cohort of 5285 children, the mean duration of follow-up in the MMRV group was 36 months (SD 8·8), in the MMR+V group was 36 months (8·5) and in the MMR group was 35 months (8·9). Varicella cases were confirmed for 37 participants in the MMRV group (two moderate to severe), 243 in the MMR+V group, and 201 in the MMR group. Second cases occurred for three participants (all in the MMR+V group). Varicella cases were moderate to severe for two participants in the MMRV group, 37 in the MMR+V group (one being a second case that followed a mild first case); and 117 in the MMR group. Efficacy of two-dose MMRV against all varicella was 94·9% (97·5% CI 92·4-96·6), and against moderate to severe varicella was 99·5% (97·5-99·9). Efficacy of one-dose varicella vaccine against all varicella was 65·4% (57·2-72·1), and against moderate to severe varicella (post hoc) was 90·7% (85·9-93·9). The most common adverse event in all groups was injection-site redness (up to 25% of participants). Within 15 days after dose one, 57·4% (95% CI 53·9-60·9) of participants in the MMRV group reported fever of 38°C or more, by contrast with 44·5% (41·0-48·1) with MMR+V, and 39·8% (33·8-46·1) with MMR. Eight serious adverse events were deemed related to vaccination (three MMRV, four MMR+V, one MMR). All resolved within the study period. INTERPRETATION: These results support the implementation of two-dose varicella vaccination on a short course, to ensure optimum protection from all forms of varicella disease. FUNDING: GlaxoSmithKline Vaccines.
650    _2
$a mladiství $7 D000293
650    _2
$a plané neštovice $x imunologie $x prevence a kontrola $7 D002644
650    _2
$a vakcína proti planým neštovicím $x aplikace a dávkování $7 D019433
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dodržování směrnic $7 D019983
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a vakcína proti spalničkám, příušnicím a zarděnkám $x aplikace a dávkování $7 D022542
650    _2
$a výsledek terapie $7 D016896
650    _2
$a kombinované vakcíny $x aplikace a dávkování $7 D017778
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bergsaker, Marianne Riise $u Department of Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
700    1_
$a Esposito, Susanna $u Pediatric Highly Intensive Care Unit, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
700    1_
$a Gothefors, Leif $u Swedish Institute for Communicable Disease Control, Stockholm, Sweden; Department of Clinical Sciences Pediatrics, Umeå University, Umeå, Sweden.
700    1_
$a Man, Sorin $u University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania.
700    1_
$a Snegova, Nadezhda $u Institute of Immunology, Moscow, Russia.
700    1_
$a Stefkovičova, Mária $u Department of Epidemiology, Regional Office of Public Health, Trencín, Slovak Republic.
700    1_
$a Usonis, Vytautas $u Vilnius University, Clinic of Paediatrics, Vilnius, Lithuania.
700    1_
$a Wysocki, Jacek $u University School of Medical Sciences, Poznan, Poland; Regional Medical Center for Mother and Child, Poznan, Poland.
700    1_
$a Douha, Martine $u GlaxoSmithKline Vaccines, Wavre, Belgium.
700    1_
$a Vassilev, Ventzislav $u GlaxoSmithKline Vaccines, Wavre, Belgium.
700    1_
$a Nicholson, Ouzama $u GlaxoSmithKline Vaccines, King of Prussia, PA, USA. Electronic address: ouzama.n.henry@gsk.com.
700    1_
$a Innis, Bruce L $u GlaxoSmithKline Vaccines, King of Prussia, PA, USA.
700    1_
$a Willems, Paul $u GlaxoSmithKline Vaccines, Wavre, Belgium.
773    0_
$w MED00010161 $t Lancet $x 1474-547X $g Roč. 383, č. 9925 (2014), s. 1313-24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24485548 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140710093531 $b ABA008
999    __
$a ok $b bmc $g 1031227 $s 862475
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 383 $c 9925 $d 1313-24 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace